AzurRx BioPharma, Inc. – NASDAQ:AZRX

Add to watchlist

$3.45

+3.30

+2254.95%

Market closed

Open in 2 days

-95.74%

month

-95.74%

quarter

-97.35%

year

Market Cap	3.43M
Enterprise value	19.42M

P/E	-1.84
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	3.83
PEG ratio	N/A
EPS	-11661519.66

Revenue	N/A
EBITDA	-32.66T
Income	-32.67T
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

AzurRx BioPharma, Inc. (NASDAQ:AZRX): Profit margin
Sep 2020	0	-5.31K
Dec 2020	0	-32.67T
Mar 2021	0	-7.68M
Jun 2021	0	-9.27M

AzurRx BioPharma, Inc. (NASDAQ:AZRX): Earnings per share (EPS)
2020-08-14	-0.11	-0.17
2021-03-31	-0.14	-0.31
2021-05-24	-0.07	-0.14
2021-08-16	-0.08	-0.16

AzurRx BioPharma, Inc. (NASDAQ:AZRX): Debt to assets
Sep 2020	16722021	2.65M	15.89%
Dec 2020	9942161	15.56M	156.55%
Mar 2021	17982893	3.58M	19.91%
Jun 2021	13776799	6.73M	48.92%

AzurRx BioPharma, Inc. (NASDAQ:AZRX): Cash Flow
Sep 2020	-2.69M	-2.80K	13.06M
Dec 2020	-5.88M	90.15K	552.39K
Mar 2021	-5.07M	0	11.05M
Jun 2021	-5.62M	-9.07M	10.78M

AzurRx BioPharma alternative data

AzurRx BioPharma, Inc. (NASDAQ:AZRX): Employee count
Aug 2023	12
Sep 2023	12
Oct 2023	12
Nov 2023	12
Dec 2023	12
Jan 2024	12
Feb 2024	12
Mar 2024	12
Apr 2024	12
May 2024	12
Jun 2024	12
Jul 2024	12

AzurRx BioPharma
Insider Trading

AzurRx BioPharma, Inc. (NASDAQ:AZRX): Insider trades (number of shares)
Period	Buy	Sel
May 2018	20000	0
Dec 2018	187128	0
Feb 2019	1766170	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	14 Feb 2019	ROSS EDMUND BURKE JR. 10 percent owner 10 percent owner	10% Convertible Note Due 2019	1,000,000	$2.5	$2,500,000
Purchase	14 Feb 2019	ROSS EDMUND BURKE JR. 10 percent owner 10 percent owner	CEDA Warrants Expiring 2020	21,429	N/A	N/A
Purchase	14 Feb 2019	ROSS EDMUND BURKE JR. 10 percent owner 10 percent owner	EBR Warrants Expiring 2020	100,000	N/A	N/A
Purchase	14 Feb 2019	ROSS EDMUND BURKE JR. 10 percent owner 10 percent owner	ADEC Warrants Expiring 2021	371,143	N/A	N/A
Purchase	14 Feb 2019	ROSS EDMUND BURKE JR. 10 percent owner 10 percent owner	ADEC Warrants Expiring 2020	273,598	N/A	N/A
Purchase	31 Dec 2018	ROSS EDMUND BURKE JR. 10 percent owner 10 percent owner	Common Stock	23,848	$1.12	$26,710
Purchase	28 Dec 2018	SHENOUDA MAGED director, officer: CHIEF FINANCIAL OFFICER director, officer: CHIEF FINANC..	Common Stock	20,000	$1.31	$26,220
Purchase	28 Dec 2018	CASAMENTO CHARLES J director director	Common Stock	9,000	$1.41	$12,690
Purchase	28 Dec 2018	SPOOR JOHAN M. director director	Common Stock	38,583	$1.3	$49,965
Purchase	28 Dec 2018	ROSS EDMUND BURKE JR. 10 percent owner 10 percent owner	Common Stock	29,575	$1.18	$34,899

AZRX insider trading transactions

AzurRx BioPharma
Latest News

Tuesday, 21 September 2021
12:47	AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today	GlobeNewsWire
Wednesday, 15 September 2021
09:20	3 Penny Stocks That Top Investors Buying Right Now	PennyStocks
Tuesday, 14 September 2021
12:59	AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M	Zacks Investment Research
07:30	AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma	GlobeNewsWire
Monday, 13 September 2021
16:40	AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript	Seeking Alpha
09:19	AzurRx BioPharma Announces Reverse Merger With First Wave Bio	Benzinga
06:00	AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications	GlobeNewsWire
Friday, 10 September 2021
12:45	AzurRx BioPharma Announces Reverse Stock Split	GlobeNewsWire
08:30	AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections	GlobeNewsWire
Thursday, 9 September 2021
08:30	AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections	GlobeNewsWire
Wednesday, 8 September 2021
08:30	AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis	GlobeNewsWire
Tuesday, 7 September 2021
16:30	AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference	GlobeNewsWire
Wednesday, 25 August 2021
10:04	3 Penny Stocks That Top Investors Are Buying Right Now	PennyStocks
Thursday, 19 August 2021
12:16	AzurRx (AZRX) Pancreatic Insufficiency Study Meets Endpoints	Zacks Investment Research
Wednesday, 18 August 2021
13:34	AZRX Stock: The Huge Trial News Lifting Little-Known AzurRX BioPharma Today	InvestorPlace
07:33	AzurRx BioPharma Shares Increase Over 40% Pre-Market: Why It Happened	Pulse2
07:05	AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)	GlobeNewsWire
Tuesday, 17 August 2021
07:00	AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of AzurRx BioPharma stock today?

One share of AzurRx BioPharma stock can currently be purchased for approximately $3.45.
When is AzurRx BioPharma's next earnings date?

Unfortunately, AzurRx BioPharma's (AZRX) next earnings date is currently unknown.
Does AzurRx BioPharma pay dividends?

No, AzurRx BioPharma does not pay dividends.
How much money does AzurRx BioPharma make?

AzurRx BioPharma has a market capitalization of 3.43M. AzurRx BioPharma made a loss 32.67M US dollars in net income (profit) last year or -$0.16 on an earnings per share basis.
What is AzurRx BioPharma's stock symbol?

AzurRx BioPharma, Inc. is traded on the NASDAQ under the ticker symbol "AZRX".
What is AzurRx BioPharma's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of AzurRx BioPharma?

Shares of AzurRx BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does AzurRx BioPharma have?

As Jul 2024, AzurRx BioPharma employs 12 workers.
When AzurRx BioPharma went public?

AzurRx BioPharma, Inc. is publicly traded company for more then 8 years since IPO on 11 Oct 2016.
What is AzurRx BioPharma's official website?

The official website for AzurRx BioPharma is azurrx.com.
Where are AzurRx BioPharma's headquarters?

AzurRx BioPharma is headquartered at 760 Parkside Ave Ste 304, Brooklyn, NEW YORK.
How can i contact AzurRx BioPharma?

AzurRx BioPharma's mailing address is 760 Parkside Ave Ste 304, Brooklyn, NEW YORK and company can be reached via phone at +1 646 699 7855.

AzurRx BioPharma, Inc.

azurrx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

+1 646 699 7855

760 Parkside Ave Ste 304
Brooklyn, NEW YORK 11226

CIK: 0001604191
ISIN: US05502L1052
CUSIP: 05502L105